Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Clear-cell metastatic renal cell carcinoma 1

Interventions

Nivolumab 8Specimen Handling 4Ipilimumab 4cabozantinib 3Sunitinib 3Radiosurgery 3pembrolizumab 2pazopanib 2Everolimus 2CTLA-4 Antigen 2Biopsy 2Axitinib 2tivozanib 1sodium-iodide symporter 1sitravatinib 1lenvatinib 1Zoledronic Acid 1Radiotherapy 1Pluvicto 1Nephrectomy 1Metastasectomy 1Magnetic Resonance Spectroscopy 1LY2510924 1Interleukin-2 1Ibandronic Acid 1Diphosphonates 1Denosumab 1Cytoreduction Surgical Procedures 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Clear-cell metastatic renal cell carcinoma × LY2510924 × Clear all
NCT01391130 2019-07-23

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Eli Lilly and Company

Phase 2 Terminated
110 enrolled 14 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡